Supernus Pharmaceuticals Inc
NASDAQ:SUPN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Supernus Pharmaceuticals Inc
NASDAQ:SUPN
|
US |
|
NetEase Inc
NASDAQ:NTES
|
CN |
|
Triputra Agro Persada Tbk PT
IDX:TAPG
|
ID |
|
C
|
Carpenter Technology Corp
F:XTY
|
US |
|
Kinarus Therapeutics Holding AG
SIX:KNRS
|
CH |
|
Nissan Chemical Corp
TSE:4021
|
JP |
|
Seadrill Ltd
F:S9AD
|
BM |
|
Loandepot Inc
F:LDD
|
US |
|
B
|
Barito Renewables Energy PT Tbk
IDX:BREN
|
ID |
|
Advanced Micro Devices Inc
NASDAQ:AMD
|
US |
Wall St Price Targets
SUPN Price Targets Summary
Supernus Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for SUPN is 64.09 USD with a low forecast of 55.55 USD and a high forecast of 69.3 USD.
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is SUPN's stock price target?
Price Target
64.09
USD
According to Wall Street analysts, the average 1-year price target for SUPN is 64.09 USD with a low forecast of 55.55 USD and a high forecast of 69.3 USD.
What is the Revenue forecast for Supernus Pharmaceuticals Inc?
Projected CAGR
8%
Over the last 13 years, the compound annual growth rate for Revenue has been 61%. The projected CAGR for the next 8 years is 8%.
What is the Gross Profit forecast for Supernus Pharmaceuticals Inc?
Projected CAGR
7%
Over the last 13 years, the compound annual growth rate for Gross Profit has been 59%. The projected CAGR for the next 8 years is 7%.
What is the Operating Income forecast for Supernus Pharmaceuticals Inc?
Projected CAGR
61%
The compound annual growth rate for Operating Income over the next 8 years is 61%.
